Ceterix Orthopaedics was issued a patent addressing a method to place a suture around a tear in support of meniscus repair.
U.S. Patent No. 9,861,354 protects products and methods—specifically, placing a circumferential compression stitch—to arthroscopically pass suture through soft tissue in very tight joint compartments. The company’s NovoStitch®Plus Meniscal Repair system is now protected by >180 issued claims related to its minimally invasive technology to treat complex tears. The system has been available in the U.S. market since 2015.
In a 2016 ORTHOKNOW® interview, Ceterix President and Chief Executive Officer John McCutcheon emphasized the importance of meniscus repair vs. meniscectomy, which he noted is under scrutiny as a meniscal treatment.
McCutcheon is seeing surgeons push to do repairs for more types of injuries that they used to think were irreparable, like radial tears.
“More and more surgeons say, ‘Look, we’ve got to repair everything,’ ” he says. “More data is coming out that a meniscectomy is not a good thing—payors and providers are paying attention. All of the literature and data shows that [repairing the meniscus] prevents arthritis later and that it’s the right thing to do.”
Ceterix Orthopaedics was issued a patent addressing a method to place a suture around a tear in support of meniscus repair.
U.S. Patent No. 9,861,354 protects products and methods—specifically, placing a circumferential compression stitch—to arthroscopically pass suture through soft tissue in very tight joint compartments. The company's...
Ceterix Orthopaedics was issued a patent addressing a method to place a suture around a tear in support of meniscus repair.
U.S. Patent No. 9,861,354 protects products and methods—specifically, placing a circumferential compression stitch—to arthroscopically pass suture through soft tissue in very tight joint compartments. The company’s NovoStitch®Plus Meniscal Repair system is now protected by >180 issued claims related to its minimally invasive technology to treat complex tears. The system has been available in the U.S. market since 2015.
In a 2016 ORTHOKNOW® interview, Ceterix President and Chief Executive Officer John McCutcheon emphasized the importance of meniscus repair vs. meniscectomy, which he noted is under scrutiny as a meniscal treatment.
McCutcheon is seeing surgeons push to do repairs for more types of injuries that they used to think were irreparable, like radial tears.
“More and more surgeons say, ‘Look, we’ve got to repair everything,’ ” he says. “More data is coming out that a meniscectomy is not a good thing—payors and providers are paying attention. All of the literature and data shows that [repairing the meniscus] prevents arthritis later and that it’s the right thing to do.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
